刚刚，FDA 结束了为期 1 天的肿瘤药物咨询委员会（ODAC）会议，讨论了 PD-1 抑制剂在临床的适应症及应用情况。会议主要涉及 3 款已上市的 PD-1 抑制剂药物，分别是：默沙东的帕博利珠单抗（pembrolizumab，K ...
BMS和默沙东方面则是主张维持现有的“全人群”适应症的标签。BMS的会议简报提到，不同药物的各项研究的评分方法和截断值存在差异，实施任何截断值都有可能让一部分患者失去获益的机会。
▎药明康德内容团队编辑默沙东（MSD）今日宣布，美国FDA已批准其重磅PD-1抑制剂Keytruda（pembrolizumab）与培美曲塞和铂类化疗联合，作为一线疗法治疗不可切除的晚期或转移性恶性胸膜间皮瘤（MPM）成年患者。恶性间皮瘤是一类起源于 ...
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Medpage Today on MSN13 天
Survival Win for Pembrolizumab in Early Triple-Negative Breast CancerPD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...
In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...
Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...
Dr. Patel：我是加州大学圣地亚哥分校肿瘤内科学教授Sandip Patel医学博士，担任WCLC ...
Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...
Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...
Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈